Geron Corp
Closed
SectorHealthcare
1.27 0.79
Overview
Share price change
24h
Min
1.21
Max
1.27
Income | 25M -3.6M |
|---|---|
Sales | 3.8M 52M |
EPS | -0.005 |
Profit margin | -7.026 |
Employees | 258 |
EBITDA | 24M 90K |
Recommendations | Buy |
|---|---|
12 Months Forecast | +157.94% upside |
Next Earnings | 5 sie 2026 |
|---|
Market Cap | -217M 789M |
|---|---|
Previous open | 0.48 |
Previous close | 1.27 |
Geron Corp Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Geron Corp Forecast
Price Target
By TipRanks
157.94% upside
12 Months Forecast
Average 3.25 USD 157.94%
High 5 USD
Low 1 USD
Based on 5 Wall Street analysts offering 12 month price targets forGeron Corp - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Geron Corp
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
